Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 312.00
Bid: 312.00
Ask: 314.00
Change: -3.00 (-0.95%)
Spread: 2.00 (0.641%)
Open: 320.00
High: 320.00
Low: 306.50
Prev. Close: 315.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BROKER RATINGS: BoA likes Dowlais; JPMorgan cuts Phoenix Group

Fri, 22nd Sep 2023 09:33

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

----------

FTSE 100

----------

UBS raises Next price target to 7,250 (6,850) pence - 'neutral'

----------

SocGen raises Next price target to 8,287 (8,239) pence - 'buy'

----------

JPMorgan raises Next price target to 7,500 (7,300) pence - 'neutral'

----------

JPMorgan raises Next price target to 7,500 (7,300) pence - 'neutral'

----------

Goldman Sachs cuts SSE price target to 2,390 (2,431) pence - 'buy'

----------

JPMorgan raises M&G price target to 195 (180) pence - 'underweight'

----------

JPMorgan raises Admiral Group price target to 1,700 (1,650) pence - 'underweight'

----------

JPMorgan cuts Phoenix Group to 'underweight' (neutral) - price target 500 (655) pence

----------

JPMorgan cuts Prudential price target to 1,500 (1,630) pence - 'overweight'

----------

JPMorgan cuts Legal & General price target to 290 (315) pence - 'overweight'

----------

RBC raises Hargreaves Lansdown target to 900 (875) pence - 'sector perform'

----------

Deutsche Bank cuts Lloyds Banking price target to 62 (63) pence - 'buy'

----------

Deutsche Bank cuts Barclays price target to 200 (230) pence - 'hold'

----------

Deutsche Bank cuts NatWest price target to 320 (370) pence - 'buy'

----------

JPMorgan raises BP price target to 600 (530) pence - 'neutral'

----------

JPMorgan raises Shell price target to 3,200 (2,750) pence - 'overweight'

----------

FTSE 250

----------

Bank of America starts Dowlais with 'buy' - price target 144 pence

----------

Jefferies cuts Victrex price target to 1,420 (1,590) pence - 'hold'

----------

JPMorgan raises Hiscox to 'overweight' (neutral) - price target 1,300 (1,200) pence

----------

JPMorgan raises Just Group price target to 125 (120) pence - 'overweight'

----------

JPMorgan cuts Lancashire to 'neutral' (overweight) - price target 715 (750) pence

----------

Berenberg cuts Mobico Group price target to 140 (220) pence - 'buy'

----------

Deutsche Bank cuts Dunelm price target to 1,310 (1,340) pence - 'buy'

----------

Deutsche Bank cuts Virgin Money UK target to 210 (220) pence - 'hold'

----------

SMALL CAP

----------

Berenberg raises DFS Furniture price target to 185 (155) pence - 'buy'

----------

JPMorgan cuts Oxford BioMedica price target to 325 (495) pence - 'neutral'

----------

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
12 Mar 2019 10:10

Oxford Biomedica enters research collaboration with Microsoft

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has entered into a research and development collaboration with Microsoft Research, it announced on Tuesday, to improve the yield and quality of next-generation gene therapy vectors using the cloud and machine learning.

Read more
23 Nov 2018 10:59

Oxford BioMedica forms new digital framework initiative

(Sharecast News) - Gene and cell therapy group Oxford BioMedica announced the formation of a new digital framework initiative on Friday, which it said would streamline the production of next-generation medicines.

Read more
25 Oct 2018 10:14

First patient successfully dosed with Oxford BioMedica's OXB-102

(Sharecast News) - Gene and cell therapy group Oxford BioMedica noted on Thursday that its partner, Axovant Sciences - a company developing innovative gene therapies for neurologic and neuromuscular diseases - has announced the successful dosing of the first patient in a clinical study of AXO-Lenti-PD, also known as OXB-102.

Read more
13 Sep 2018 15:46

'Transformative year' sees Oxford Biomedica profit from two huge contracts

(Sharecast News) - Biopharmaceutical company Oxford Biomedica saw its shares rise on Thursday after its first half gross income more than doubled due to two huge contracts.

Read more
22 May 2018 16:13

UK Shareholder Meetings Calendar - Next 7 Days

Wednesday 23 MayBovis Homes GroupSt James's Place Keller GroupGamma Emerging

Read more
4 May 2018 11:57

Oxford BioMedica To Cut Share Capital Through Consolidation (ALLISS)

LONDON (Alliance News) - Oxford BioMedica PLC said Friday it is proposing reducing the issued share capital of the company by a factor of 50 through a share capital consolidation.On Oxford

Read more
15 Mar 2018 11:45

Oxford Biomedica Loss Narrows, Revenue Grows In Transformational 2017

LONDON (Alliance News) - Gene therapy firm Oxford Biomedica PLC said Thursday its 2017 loss narrowed after revenue grew significantly on product progress and finance costs in

Read more
9 Mar 2018 17:16

Oxford BioMedica To Raise GBP21 Million Via Discounted Share Issue (ALLISS)

LONDON (Alliance News) - Oxford BioMedica PLC said Friday it intends to raise GBP20.5 million via a accelerated share book build process to fund the expansion a

Read more
10 Oct 2016 14:19

Oxford BioMedica's RetinoStat achieves 'favourable safety profile' in tests

(ShareCast News) - AIM-listed pharmaceutical Oxford BioMedica's RetinoStat, the first ocular lentiviral gene therapy to be administered in humans, demonstrated a "favourable safety profile with no serious adverse events" in its phase one study. Results of the study, which were previously published i

Read more
28 Jul 2016 09:05

Oxford BioMedica Gets Approval To Manufacture Drugs At New Facilities

Read more
7 Jun 2016 06:48

Oxford BioMedica Signs New Non-Exclusive Licence Deal With MolMed

Read more
2 Jun 2016 11:03

LONDON MARKET MIDDAY: Platinum Firm Gleams Ahead Of ECB, OPEC Outcomes

Read more
2 Jun 2016 09:16

Oxford Biomedica Signs Collaboration Deal With Green Cross LabCell

Read more
31 May 2016 15:04

UK Shareholder Meetings Calendar - Next 7 Days

Read more
24 May 2016 10:42

DIRECTOR DEALINGS: Oxford BioMedica Chairman Ups Interest

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.